Loading...
•
Jun 30, 2020
Guardant Health Q2 2020 Earnings Report
Reported a 23% revenue increase compared to the prior year period.
Key Takeaways
Guardant Health reported a 23% increase in revenue for the second quarter of 2020, driven by growth in both precision oncology and development services. The company's cash position was strengthened by a public offering, ending the quarter with $1.1 billion in cash, cash equivalents and marketable securities.
Revenue of $66.3 million for the second quarter of 2020, an increase of 23% over the corresponding period of 2019
Precision oncology revenue of $51.0 million, an increase of 21% over the corresponding period of 2019
Reported 13,694 tests to clinical customers and 2,805 tests to biopharmaceutical customers in the second quarter of 2020, representing an increase of 15% and a decrease of 47%, respectively, over the second quarter of 2019
Ended the second quarter with $1.1 billion cash, cash equivalents and marketable securities
Revenue by Segment
Forward Guidance
Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...